197 related articles for article (PubMed ID: 20498076)
21. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
Sapra P; Wang M; Bandaru R; Zhao H; Greenberger LM; Horak ID
Nucleosides Nucleotides Nucleic Acids; 2010 Feb; 29(2):97-112. PubMed ID: 20391197
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines.
Sartorius UA; Krammer PH
Int J Cancer; 2002 Feb; 97(5):584-92. PubMed ID: 11807782
[TBL] [Abstract][Full Text] [Related]
23. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
24. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug.
Wang Y; Minko T
Biochem Pharmacol; 2004 Nov; 68(10):2031-42. PubMed ID: 15476674
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel.
Sonnemann J; Gekeler V; Ahlbrecht K; Brischwein K; Liu C; Bader P; Müller C; Niethammer D; Beck JF
Cancer Lett; 2004 Jun; 209(2):177-85. PubMed ID: 15159020
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effect of Ubenimex combined with fluorouracil on multiple drug resistance and P-glycoprotein expression level in non-small lung cancer.
Wan J; Ling XA; Wang J; Ding GG; Wang X
J Cell Mol Med; 2020 Nov; 24(21):12840-12847. PubMed ID: 32945069
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
29. Nobiletin Enhances Chemosensitivity to Adriamycin through Modulation of the Akt/GSK3β/β⁻Catenin/MYCN/MRP1 Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells.
Moon JY; Manh Hung LV; Unno T; Cho SK
Nutrients; 2018 Nov; 10(12):. PubMed ID: 30486290
[TBL] [Abstract][Full Text] [Related]
30. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
31. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
[TBL] [Abstract][Full Text] [Related]
32. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.
Kang HK; Lee E; Pyo H; Lim SJ
Mol Cancer Ther; 2005 Sep; 4(9):1358-63. PubMed ID: 16170027
[TBL] [Abstract][Full Text] [Related]
33. Stephania Tetrandra and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts.
Jin L; Xu M; Luo XH; Zhu XF
Am J Chin Med; 2017; 45(2):385-401. PubMed ID: 28231742
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
36. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
37. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
38. Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.
Muench D; Rezzoug F; Thomas SD; Xiao J; Islam A; Miller DM; Sedoris KC
PLoS One; 2019; 14(1):e0211046. PubMed ID: 30682194
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
40. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]